Durvalumab Generics - Manufacturers & Suppliers
Imfinzi® (US & EU)
| Product/Composition:- | Durvalumab |
|---|---|
| Strength:- | 120 mg/4 mL, 500 mg/10 mL |
| Form:- | Injection |
| Reference Brands:- | Imfinzi® (US & EU) |
| MOQ | As per the manufacturer batch size |
| Get Quote Send Enquiry on WhatsApp | |
Durvalumab (Imfinzi®) is a PD-L1 checkpoint inhibitor used for urothelial carcinoma and NSCLC treatment. Available as sterile intravenous infusion vials (120 mg/4 mL, 500 mg/10 mL), it complies with EU-GMP and USFDA standards. Offered for B2B supply, hospital tenders, and licensing in regulated markets.
Durvalumab (Imfinzi®) is a PD-L1 immune checkpoint inhibitor indicated for urothelial carcinoma and non-small cell lung cancer. Provided as sterile intravenous infusion vials (120 mg/4 mL and 500 mg/10 mL), Durvalumab is manufactured under EU-GMP and USFDA standards. Available for B2B supply, contract manufacturing, and licensing, it supports hospital tenders and oncology distributors with full regulatory documentation. This monoclonal antibody enhances anti-tumor immunity by blocking PD-L1, making it a critical drug in immuno-oncology portfolios across the US and European markets.